BRNS vs IMCR vs ADCT vs FATE

For growth investors, Immunocore Holdings plc (IMCR) is the stronger pick with 20.

0% revenue growth year-over-year, versus -100. 0% for Barinthus Biotherapeutics plc (BRNS). Analysts rate Immunocore Holdings plc (IMCR) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunocore Holdings plc (IMCR) delivered a total return of -24.

0%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: FATE returned +40. 5% versus BRNS's -95. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Immunocore Holdings plc (IMCR) is the lower-risk stock at 0.

86β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 152% more volatile than IMCR relative to the S&P 500. On balance sheet safety, Immunocore Holdings plc (IMCR) carries a lower debt/equity ratio of 11% versus 38% for Fate Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Immunocore Holdings plc (IMCR) is pulling ahead at 20.

0% versus -100. 0% for Barinthus Biotherapeutics plc (BRNS). On earnings-per-share growth, the picture is similar: Immunocore Holdings plc grew EPS 48. 0% year-over-year, compared to -5. 8% for Barinthus Biotherapeutics plc. Over a 3-year CAGR, IMCR leads at 27. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Barinthus Biotherapeutics plc (BRNS) is the more profitable company, earning 0.

0% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRNS leads at 0. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — IMCR leads at 97. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Immunocore Holdings plc (IMCR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

86)). Fate Therapeutics, Inc. (FATE) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMCR: -29. 1%, FATE: +40. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BRNS is a small-cap quality compounder stock; IMCR is a small-cap high-growth stock; ADCT is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.